2009
DOI: 10.1086/596318
|View full text |Cite
|
Sign up to set email alerts
|

Helicobacter pyloriVacuolating Cytotoxin Inhibits Duodenal Bicarbonate Secretion by a Histamine‐Dependent Mechanism in Mice

Abstract: H. pylori VacA inhibits PGE2-stimulated duodenal epithelial HCO3- secretion by a histamine-dependent mechanism. This effect likely contributes to the damaging effect of H. pylori in the duodenal mucosa.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2009
2009
2020
2020

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 13 publications
(4 citation statements)
references
References 39 publications
0
4
0
Order By: Relevance
“…The antibody-based procedures used in this study comply with the recommendations made by the British Journal of Pharmacology. Immunohistocytochemistry was carried out as described previously (Tuo et al, 2009). Briefly, the slides with jejunal tissues from C57BL/6 mice or with IECs were incubated with an anti-STIM1…”
Section: Immunohistocytochemistrymentioning
confidence: 99%
“…The antibody-based procedures used in this study comply with the recommendations made by the British Journal of Pharmacology. Immunohistocytochemistry was carried out as described previously (Tuo et al, 2009). Briefly, the slides with jejunal tissues from C57BL/6 mice or with IECs were incubated with an anti-STIM1…”
Section: Immunohistocytochemistrymentioning
confidence: 99%
“…Through the p38/ATF-2 cascade, COX-2 is upregulated, which leads to increased production of prostaglandin E 2 (PGE 2 ; Hisatsune et al, 2007). Conversely, in mice VacA inhibits PGE 2 -stimulated duodenal epithelial bicarbonate (HCO3) secretion by inducing the release of mucosal histamine (Tuo et al, 2009). While the reason for this discrepancy in VacA mediated increase in PGE 2 effects is unclear, it should be noted that decreased duodenal epithelial HCO3secretion is associated with duodenal ulcers and may leave the mucosal layer less able to repair itself (Isenberg et al, 1987).…”
Section: Vaca Functionsmentioning
confidence: 99%
“…Considering the findings in the present study, it is assumed that beyond treatment of constipation, irritable bowel syndrome and enteropathy, lubiprostone may have potential to be used more for protection against gastritis and peptic ulcer diseases, since it does stimulate the secretion of HCO 3 in both the stomach and duodenum. Furthermore, because duodenal HCO 3 secretion was shown to be impaired in patients with Helicobacter pylori (Tuo et al 2004;Tuo et al 2009), it is also possible that lubiprostone may be useful for treatment of Helicobater pylorirelated diseases. K. Takeuchi, S. Hayashi, K. Amagase…”
Section: Discussionmentioning
confidence: 99%